The Food and Drug Administration (FDA)-approved analgesic drug R-ketorolac (Toradol) inhibits Cdc42 and Rac1 in ovarian cancer cells and is currently in clinical trials (NCT02470299) [258]. This evidence concerns the gene RAC1 and ovarian cancer.